Evommune (EVMN) EPS (Basic) (2024 - 2026)

Evommune (EVMN) reported EPS (Basic) of -$0.64 for Q1 2026, up 93.25% year-over-year from -$0.33 in Q1 2025, and down 104.23% quarter-over-quarter from $15.14 in Q4 2025.

Evommune (EVMN) EPS (Basic) (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of EPS (Basic) data on file, last reported at -$0.64 in Q1 2026.

  • EPS (Basic) for Q1 2026 came in at -$0.64, up 93.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.05 (changed N/A YoY), and the FY2025 annual result was -$11.22, up 75.23% from the prior year.
  • EPS (Basic) fell to -$0.64 in Q1 2026 per EVMN's latest filing, from $15.14 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $15.14 in Q4 2025 and troughed at -$14.6 in Q4 2024.
  • A 3-year average of -$4.69 and a median of -$8.78 in 2025 frame the typical range for EPS (Basic).
  • On a YoY basis, EPS (Basic) climbed as much as 203.7% in 2025 and fell as far as 22.92% in 2025.
  • A 3-year view of EPS (Basic) shows it stood at -$14.6 in 2024, then soared by 203.7% to $15.14 in 2025, then sank by 104.23% to -$0.64 in 2026.
  • Business Quant data shows EVMN's EPS (Basic) at -$0.64 in Q1 2026, $15.14 in Q4 2025, and -$8.07 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -0.68
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 3.06
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.00
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 0.00
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 0.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 0.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 4.06
9 Abivax 91.96 Bn 91.96 Bn - -0.06
10 Evommune 695.29 Mn 483.82 Mn - -0.64

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.64
Dec 31, 2025 15.14
Sep 30, 2025 -8.07
Mar 31, 2025 -9.48
Dec 31, 2024 -14.60
Sep 30, 2024 -10.47